^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATOR-1015

    i
    Other names: ATOR-1015, ADC-1015
    Associations

    News

    Trials
    Company:
    Alligator Biosci, BioInvent
    Drug class:
    CTLA4 inhibitor, OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies (SITC 2020)
    Following the dose escalation phase, an expansion cohort for patients with advanced malignant melanoma will be initiated. Ethics Approval The study is approved by the Ethic Boards in Sweden and Denmark.
    Clinical • P1 data • PK/PD data • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    ATOR-1015
    over3years
    [VIRTUAL] Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies (SITC 2020)
    Following the dose escalation phase, an expansion cohort for patients with advanced malignant melanoma will be initiated. Ethics Approval The study is approved by the Ethic Boards in Sweden and Denmark.
    Clinical • P1 data • PK/PD data • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    ATOR-1015
    4years
    [VIRTUAL] A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody. (ASCO 2020)
    The dosing of ATOR-1015 has been safe and well-tolerated up to 200 mg. Dose escalation continues and the current dose level under evaluation is 400 mg. Research Funding: Alligator Bioscience AB
    Clinical • P1 data
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TNFRSF4 (TNF Receptor Superfamily Member 4)
    |
    ATOR-1015
    4years
    [VIRTUAL] A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody (AACR-I 2020)
    The dosing of ATOR-1015 has been safe and well-tolerated up to 100 mg. Dose escalation continues and the current dose level is 200 mg.
    Clinical • P1 data
    |
    TNFRSF4 (TNF Receptor Superfamily Member 4)
    |
    ATOR-1015